Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.

US FDA approves Novartis' kidney disease drug. By Sriparna Roy. August 7, 2024 10:29 PM UTC Updated August 7, 2024. The logo of Swiss drugmaker Novartis is pictured at the ...

FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease. On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first ...

C3G is a progressive and ultra-rare kidney disease that is typically diagnosed in young adults and often progresses to kidney failure. Per NVS, this is the first and only treatment approved for ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce ...